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Association Between Donor-Recipient HLA-DR Compatibility and 
Cytomegalovirus Hepatitis and Chronic Rejection in 
Liver Transplantation 
R. Manez, L.T. White, S. Kusne, M. Martin, A.J. Demetris, T.E. Starzl, and R.J. Duquesnoy 
PREVIOUS studies in liver transplant patients have demonstrated that liver allografts matched for HLA. 
especially HLA-DR, have lower survival rates, raising the 
concept that HLA plays a dualistic role in liver transplan-
tation. HLA matching will reduce rejection but may aug-
ment other major histocompatibility complex (MHC) re-
stricted cellular immune mechanisms of liver allograft 
injury. 1.2 These mechanisms could be related to immune 
responses, viral infections, and autoimmune disease. 
Cytomegalovirus (CMV) infection is a major pathogen 
for transplant patients. The mechanisms of CMV -induced 
graft injury involve direct viral effects and cell-mediated 
immune responses. Several in vitro studies have demon-
strated that lymphocyte responsiveness to CMV-infected 
cells is MHC restricted.3 •4 Therefore. we postulated that 
HLA antigen sharing between donor and recipient might 
influence the development of CMV hepatitis after liver 
transplantation. 
In liver transplant patients CMV infection is associated 
with the development of the vanishing bile duct syndrome, 
a manifestation of chronic rejection.s Also, the incidence 
of vanishing bile duct syndrome appears to be higher for 
liver transplants from donors with HLA-DR matches.2 
This report summarizes our studies on the influence of 
HLA matching on CMV hepatitis and chronic liver trans-
plant rejection. A more detailed study will be published 
elsewhere.6 
MATERIALS AND METHODS 
Study Population and Immunosuppression 
This study was conducted on 399 adult liver transplant patients 
who had survived for at least 3 months after surgery. All patients 
received FK 506 and the protocol of FK 506 treatment is de-
scribed elsewhere.' Rejection episodes were treated with steroids 
as a bolus or by tapered doses. Steroid-resistant rejection epi-
sodes were treated with OKTI. 
Serology 
Complete donor-recipient HLA-A, B, DR, DQ typing was done 
for 355 liver transplant cases using standard lymphocytotoxicity 
assays. Pretransplant CMV serological status of donor and recip-
ient was available for 262 transplant cases. 
Diagnosis of CMV Hepatitis 
This study focused on CMV hepatitis rather than CMV infection 
of liver transplant patients. The diagnosis of CMV hepatitis was 
based on typical inclusion bodies or direct immunoperoxidase 
detection of CMV early antigen in liver biopsies. 
Diagnosis of Chronic Rejection 
Histological criteria for chronic rejection are described elsewhere8 
and include lymphocytic bile duct damage in 50% or more of the 
portal triads, with evidence of bile duct loss and hepatocanalicular 
cholestasis. 
RESULTS 
CMV hepatitis developed in 25 of 355 liver transplant 
patients, 17 (68%) of which shared at least one HLA-DR 
antigen with the donor. In contrast, HLA-DR sharing was 
found in 35% of 330 patients without CMV hepatitis (P = 
.005). An HLA-DR match increased the relative risk of 
CMV hepatitis by a factor of 3.6. No significant associa-
tions were found between CMV hepatitis and donor-
recipient sharing of HLA-A, HLA-B. and HLA-DQ anti-
gens. 
In the group of 39 seronegative patients with CMV 
positive liver grafts, the incidence of CMV hepatitis was 
44% for HLA-DR matched grafts but only 14% for 
HLA-DR mismatched grafts (P = .07). Similarly, 
HLA-DR matching increased the incidence of CMV hep-
atitis in CMV seropositive patients from 2% to 12% (P = 
.006). 
During a follow-up between 10 and 24 months after 
transplantation, 29 patients (8%) developed chronic rejec-
tion. An earlier onset and a higher incidence of chronic 
rejection was seen in the CMV hepatitis group (24% vs 6%; 
P < .005). 
No significant differences were found in the incidence of 
chronic rejection of liver transplants matched or mis-
matched for HLA-A, B, DR, or DQ. However, HLA-DR 
sharing was associated with an earlier onset of chronic 
rejection in patients irrespective of CMV hepatitis status 
(median onset 130 days vs 356 days; P < .01). 
DISCUSSION 
The higher incidence of CMV hepatitis in HLA-DR 
matched liver transplants is consistent with the concept of 
a dualistic role of HLA. According to this concept HLA 
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HLA ANTIGEN SHARING 
compatibility decreases graft rejection but may augment 
other cellular immune mechanisms of transplant injury, 
e~oeciallv those mediated by MHC restricted Iympho-
cy·tes. I In vitro studies have demonstrated HLA restricted 
lymphocyte responses to CMY and it is possible that 
similar mechanisms operate within the CMY infection of 
HLA compatible liver allografts. Because no associations 
were found with HLA-A, B, or DQ sharing, it seems that 
HLA-DR gene products playa critical role in the postu-
lated HLA restricted CMY-,specific cellular injury of liver 
allografts. 
This study has shown that liver transplant recipients 
with CMY hepatitis experience more chronic rejection. 
This is consistent with the previously reported association 
between CMY infection and the vanishing bile duct syn-
drome in liver transplant patients and that HLA-DR 
matching of the liver donor represented an additional risk 
factor. s Our data suggest that HLA-DR matching in-
creases the risk of CMY hepatitis, which then leads to a 
higher incidence of chronic rejection. 
HLA-DR matching appears associated with an earlier 
onset but not a higher frequency of chronic rejection. 
Because the HLA-DR match effect was also seen in 
patients without CMY hepatitis, it seems that additional 
HLA-DR restricted lymphocyte responses to as yet unde-
fined antigens may contribute to accelerated chronic rejec-
tion of the liver allograft. 
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In summary, these results expand the concept of the 
dualistic role of HLA in liver transplantation. A novel 
a~pect is that HLA-DR matching will not only increase the 
risk of CMY hepatitis but also accelerate chronic rejection 
of liver allografts. A better understanding of the different 
HLA-associated immune mechanisms within the liver al-
lograft may lead to improved management strategies in 
hepatic transplantation. 
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